GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Asset Turnover
中文

Homology Medicines (Homology Medicines) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Homology Medicines's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Homology Medicines's Total Assets for the quarter that ended in Dec. 2023 was $112.31 Mil. Therefore, Homology Medicines's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Homology Medicines's annualized ROE % for the quarter that ended in Dec. 2023 was -79.99%. It is also linked to ROA % through Du Pont Formula. Homology Medicines's annualized ROA % for the quarter that ended in Dec. 2023 was -57.41%.


Homology Medicines Asset Turnover Historical Data

The historical data trend for Homology Medicines's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Asset Turnover Chart

Homology Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial 0.01 0.01 0.14 0.02 0.01

Homology Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Homology Medicines's Asset Turnover

For the Biotechnology subindustry, Homology Medicines's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Homology Medicines's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Homology Medicines's Asset Turnover falls into.



Homology Medicines Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Homology Medicines's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=1.156/( (228.47+84.564)/ 2 )
=1.156/156.517
=0.01

Homology Medicines's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (140.063+84.564)/ 2 )
=0/112.3135
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Homology Medicines  (NAS:FIXX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Homology Medicines's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-64.476/80.601
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-64.476 / 0)*(0 / 112.3135)*(112.3135/ 80.601)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.3935
=ROA %*Equity Multiplier
=-57.41 %*1.3935
=-79.99 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Homology Medicines's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-64.476/112.3135
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-64.476 / 0)*(0 / 112.3135)
=Net Margin %*Asset Turnover
= %*0
=-57.41 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Homology Medicines Asset Turnover Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Homology Medicines (Homology Medicines) Business Description

Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Executives
Paul Alloway officer: See Remarks C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour officer: Chief Scientific Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum officer: Chief Commercial Officer C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith officer: CFO, Treasurer & Secretary C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos director, officer: President & CEO C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly officer: See Remarks C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn officer: Chief Medical Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn director, 10 percent owner, other: *Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty officer: Chief Operating Officer C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109

Homology Medicines (Homology Medicines) Headlines

From GuruFocus